###begin article-title 0
###xml 106 110 <span type="species:ncbi:10116">rats</span>
Enhanced muscarinic M1 receptor gene expression in the corpus striatum of streptozotocin-induced diabetic rats
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 1134 1137 1134 1137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1285 1288 1285 1288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1305 1306 1305 1306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 409 413 <span type="species:ncbi:10116">rats</span>
###xml 746 750 <span type="species:ncbi:10116">rats</span>
###xml 784 788 <span type="species:ncbi:10116">rats</span>
###xml 1239 1243 <span type="species:ncbi:10116">rats</span>
###xml 1423 1427 <span type="species:ncbi:10116">rats</span>
###xml 1543 1547 <span type="species:ncbi:10116">rats</span>
Acetylcholine (ACh), the first neurotransmitter to be identified, regulate the activities of central and peripheral functions through interactions with muscarinic receptors. Changes in muscarinic acetylcholine receptor (mAChR) have been implicated in the pathophysiology of many major diseases of the central nervous system (CNS). Previous reports from our laboratory on streptozotocin (STZ) induced diabetic rats showed down regulation of muscarinic M1 receptors in the brainstem, hypothalamus, cerebral cortex and pancreatic islets. In this study, we have investigated the changes of acetylcholine esterase (AChE) enzyme activity, total muscarinic and muscarinic M1 receptor binding and gene expression in the corpus striatum of STZ - diabetic rats and the insulin treated diabetic rats. The striatum, a neuronal nucleus intimately involved in motor behaviour, is one of the brain regions with the highest acetylcholine content. ACh has complex and clinically important actions in the striatum that are mediated predominantly by muscarinic receptors. We observed that insulin treatment brought back the decreased maximal velocity (Vmax) of acetylcholine esterase in the corpus striatum during diabetes to near control state. In diabetic rats there was a decrease in maximal number (Bmax) and affinity (Kd) of total muscarinic receptors whereas muscarinic M1 receptors were increased with decrease in affinity in diabetic rats. We observed that, in all cases, the binding parameters were reversed to near control by the treatment of diabetic rats with insulin. Real-time PCR experiment confirmed the increase in muscarinic M1 receptor gene expression and a similar reversal with insulin treatment. These results suggest the diabetes-induced changes of the cholinergic activity in the corpus striatum and the regulatory role of insulin on binding parameters and gene expression of total and muscarinic M1 receptors.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1202 1204 1202 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1205 1207 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1344 1346 1344 1346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1350 1352 1350 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 1368 1369 1368 1369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1372 1374 1372 1374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1379 1381 1379 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 1424 1429 1420 1425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 1443 1445 1439 1441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1450 1452 1446 1448 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1471 1475 1463 1467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i/o </sub>
###xml 1485 1486 1477 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1561 1563 1553 1555 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1568 1570 1560 1562 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1707 1709 1699 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1710 1712 1702 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 1131 1135 <span type="species:ncbi:10116">rats</span>
###xml 1674 1677 <span type="species:ncbi:10116">rat</span>
###xml 2026 2029 <span type="species:ncbi:10116">rat</span>
The most and well known effects of diabetes mellitus on CNS is dysfunction of neurotransmitters, which is secondary to the metabolic disorders such as hyperglycemia and acidosis. It has been proposed that an unbalanced autonomic nervous system may be a major cause of the metabolic syndrome [1] Diabetes mellitus have also been reported to be accompanied by a number of behavioral and hormonal abnormalities, including hyperphagia, reduced motor activity [2,3]. CNS abnormalities including neuronal atrophy and axonal degenerations [4,5] are also associated with diabetes. The altered levels of neurotransmitter in specific brain areas in patients with diabetes mellitus [6] and in animals with experimental diabetes [7-12] have been documented and implicated in the CNS disorders. ACh, a major neurotransmitter from autonomic nervous system, regulates the cholinergic stimulation of insulin secretion, through interactions with muscarinic receptors. Recently we have reported that muscarinic M1 receptor gene expressions were decreased in the cerebral cortex, brainstem, hypothalamus and pancreatic islets of STZ induced diabetic rats and insulin modulates the binding parameters and gene expression [13,14]. Acetylcholine muscarinic receptors, members of the superfamily of G protein-coupled receptors, are classified pharmacologically into M1 to M5 subtypes, with M1, M3 and M5 receptors preferentially coupling to Galphaq/11 proteins and M2 and M4 receptors to Galphai/o proteins [9]. All five muscarinic receptors are expressed by striatal neurones, with M1 and M4 receptors as the predominant subtypes, conforming together nearly 80% of the receptor population in the rat as shown by immunodetection [15,16] The main objective of the present study was to determine whether uncontrolled hyperglycemia, as a consequence of diabetes, altered the acetylcholine esterase enzyme activity, total and muscarinic M1 receptor binding parameters and muscarinic M1 receptor gene expression and the regulatory role of insulin in the rat corpus striatum.
###end p 4
###begin title 5
Materials and methods
###end title 5
###begin p 6
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Biochemicals used in the present study were purchased from Sigma Chemical Co., St. Louis, USA. All other reagents were of analytical grade purchased locally. Quinuclidinyl benzilate, L- [Benzilic-4,4'-3H], ([3H] QNB)(Sp. Activity 42 Ci/mmol) was purchased from NEN life sciences products Inc., Boston, U.S.A. Tri-reagent kit was purchased from MRC, USA. Real Time PCR Taqman probe assays on demand were purchased from Applied Biosystems, Foster City, CA, USA.
###end p 6
###begin p 7
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 980 983 980 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 11 22 <span type="species:ncbi:10116">Wistar rats</span>
###xml 160 164 <span type="species:ncbi:10116">Rats</span>
###xml 363 367 <span type="species:ncbi:10116">rats</span>
###xml 663 667 <span type="species:ncbi:10116">rats</span>
###xml 948 952 <span type="species:ncbi:10116">rats</span>
###xml 954 958 <span type="species:ncbi:10116">Rats</span>
Male adult Wistar rats of 180-240 g body weight were used for all experiments. They were housed in separate cages under 12 hour light and 12 hour dark periods. Rats have free access to standard food and water ad libitum. All animal care and procedures were in accordance with the Institutional and National Institute of Health guidelines. Diabetes was induced in rats by single intrafemoral injection of streptozotocin freshly dissolved in 0.1 M citrate buffer, pH 4.5, under anesthesia [17]. Streptozotocin was given at a dose of 55 mg/Kg body weight [18,19]. Animals were divided into the following groups: i) Control ii) diabetic iii) insulin-treated diabetic rats. Each group consisted of 6-8 animals. The insulin-treated diabetic group received subcutaneous injections (1 Unit/kg body weight) of Lente and Plain insulin (Boots India) daily during the entire period of the experiment. The last injection was given 24 hrs before sacrificing the rats. Rats were sacrificed on 15th day by decapitation. The corpus striatum was dissected out quickly over ice according to the procedure of Glowinski and Iversen 1966[20], the tissues were stored at -70degreesC until assayed.
###end p 7
###begin title 8
Estimation of blood glucose
###end title 8
###begin p 9
###xml 203 206 203 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 222 225 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 235 238 235 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
Blood glucose was estimated by the spectrophotometric method using glucose oxidase-peroxidase reactions. Blood samples were collected from the tail vein at 0 hours (Before the start of the experiment), 3rd day, 6th day, 10th day and 14th day and the glucose levels were estimated. Blood samples were collected 3 hrs after the administration of morning dose. The results were expressed in terms of milligram per deciliter of blood.
###end p 9
###begin title 10
Acetylcholine Esterase Assay
###end title 10
###begin p 11
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Acetylcholine esterase asssay was done using the spectrophotometric method of Ellman et al, (1961) [21]. The corpus striatum homogenate (10%) was prepared in sodium phosphate buffer (30 mM, pH-7). One ml of 1% Triton x 100 was added to the homogenate to release the membrane bound enzyme and centrifuged at 10,000 x g for 30 minutes at 4degreesC. Different concentrations of acetylthiocholine iodide were used as substrate. The mercaptan formed as a result of the hydrolysis of the ester reacts with an oxidising agent 5,5'-dithiobis (2-Nitrobenzoate) absorbs at 412 nm.
###end p 11
###begin title 12
Total Muscarinic and muscarinic M1 receptor binding studies in the corpus striatum
###end title 12
###begin p 13
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
[3H]QNB binding assay in corpus striatum was done according to the modified procedure of Yamamura and Snyder (1981) [22]. Corpus striatum was homogenised in a polytron homogeniser with 20 volumes of cold 50 mM Tris-HCl buffer, containing 1 mM EDTA, pH.7.4. The supernatant was then centrifuged at 30,000 x g for 30 minutes and the pellets were resuspended in appropriate volume of Tris-HCl-EDTA buffer.
###end p 13
###begin p 14
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 363 364 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 427 430 424 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 434 437 431 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
Total muscarinic receptor binding parameter assays were done using different concentrations i.e., 0.1-2.5 nM of [3H] QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 mul containing appropriate protein concentrations (200-250 mug). Non-specific binding was determined using 100 muM atropine. Competition studies were carried out with 1 nM [3H]QNB in each tube with atropine concentrations varying from 10-9 - 10-4 M atropine. Tubes were incubated at 22degreesC for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by three successive washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
###end p 14
###begin p 15
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 352 353 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 419 422 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 426 429 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
Muscarinic M1 receptor binding assays were done using different concentrations i.e., 0.1-2.5 nM of [3H]QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 mul containing appropriate protein concentrations (200-250 mug). Non-specific binding was determined using 100 muM pirenzepine. Competition studies were carried out with 1 nM [3H]QNB in each tube with pirenzepine concentrations varying from 10-9 - 10-4 M. Tubes were incubated at 22degreesC for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by three successive washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
###end p 15
###begin title 16
Protein determination
###end title 16
###begin p 17
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 69 75 <span type="species:ncbi:9913">bovine</span>
Protein was measured by the method of Lowry et al, (1951) [23] using bovine serum albumin as standard. The intensity of the purple blue colour formed was proportional to the amount of protein, which was read in a spectrophotometer at 660 nm
###end p 17
###begin title 18
Receptor data analysis
###end title 18
###begin p 19
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 209 212 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 664 666 664 666 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
The receptor binding parameters were determined using Scatchard analysis [24]. The specific binding was determined by subtracting non-specific binding from the total. The binding parameters, maximal binding (Bmax) and equilibrium dissociation constant (Kd), were derived by linear regression analysis by plotting the specific binding of the radioligand on X-axis and bound/free on Y-axis using Sigma plot software (version 2.0, Jandel GmbH, Erkrath, Germany). The maximal binding is a measure of the total number of receptors present in the tissue and the equilibrium dissociation constant is the measure of the affinity of the receptors for the radioligand. The Kd is inversely related to receptor affinity.
###end p 19
###begin title 20
Displacement curve analysis
###end title 20
###begin p 21
###xml 233 236 224 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 255 257 246 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 329 331 320 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
The displacement data were analysed by nonlinear regression using GraphPad PRISMtrade mark software, GraphPad Inc., San Diego, USA. The concentration of the competing drug that competes for half the specific binding was defined as EC50 which is same as IC50. The affinity of the receptor for the competing drug is designated as Ki and is defined as the concentration of the competing ligand that will bind to half the binding sites at equilibrium in the absence of radioligand or other competitors. The Hill slope was used to indicate a one or two-sited model of curve-fitting.
###end p 21
###begin title 22
Analysis of gene expression by Real-Time PCR
###end title 22
###begin p 23
###xml 58 62 <span type="species:ncbi:10116">rats</span>
RNA was isolated from the corpus striatum of experimental rats using the Tri reagent (MRC, USA). Total cDNA synthesis was performed using ABI PRISM cDNA arhive kit in 0.2 ml microfuge tubes. The reaction mixture of 20 mul contained 0.2 mug total RNA, 10 x RT buffer, 25 x dNTP mixture, 10 x random primers, MultiScribe RT (50 U/mul) and RNase free water. The cDNA synthesis reactions were carried out at 25degreesC for 10 minutes and 37degreesC for 2 hours using an Eppendorf Personal Cycler. Real-time PCR assays were performed in 96-well plates in ABI 7300 real-time PCR instrument (Applied Biosystems). The primers and probes were purchased from Applied Biosystems, Foster City, California, USA. The TaqMan reaction mixture of 20 mul contained 25 ng of total RNA-derived cDNAs, 200 nM each of the forward primer, reverse primer, and TaqMan probe for Muscarinic M1 receptor gene and endogenous control (beta-actin) and 12.5 mul of Taqman 2x Universal PCR Master Mix (Applied Biosystems) and the volume was made up with RNAse free water. The following thermal cycling profile was used (40 cycles): 50degreesC for 2 min, 95degreesC for 10 min, 95degreesC for 15 sec and 60degreesC for 1 min.
###end p 23
###begin p 24
###xml 470 477 455 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Target </sub>
###xml 481 491 466 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-actin</sub>
###xml 564 571 534 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Control</sub>
###xml 627 638 597 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;</sup>
###xml 679 690 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;</sup>
Fluorescence signals measured during amplification were considered positive if the fluorescence intensity was 20-fold greater than the standard deviation of the baseline fluorescence. The DeltaDeltaCT method of relative quantification was used to determine the fold change in expression. This was done by first normalizing the resulting threshold cycle (CT) values of the target mRNAs to the CT values of the internal control beta-actin in the same samples (DeltaCT = CTTarget - CTbeta-actin). It was further normalize with the control (DeltaDeltaCT = DeltaCT - CTControl). The fold change in expression was then obtained as (2-DeltaDeltaCT) and the graph was plotted using log 2-DeltaDeltaCT.
###end p 24
###begin title 25
Statistics
###end title 25
###begin p 26
Statistical evaluations were done by ANOVA, expressed as mean +/- S.E.M using InStat (Ver.2.04a) computer programme.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 27 31 <span type="species:ncbi:10116">rats</span>
###xml 205 209 <span type="species:ncbi:10116">rats</span>
###xml 235 239 <span type="species:ncbi:10116">rats</span>
Blood glucose level of all rats before streptozotocin administration was within the normal range. Streptozotocin administration led to a significant increase (p < 0.001) in blood glucose level of diabetic rats when compared to control rats. Insulin treatment was able to significantly reduce (p < 0.001) the increased blood glucose level to near the control value when compared to diabetic group (Table 1)
###end p 28
###begin p 29
###xml 44 48 <span type="species:ncbi:10116">rats</span>
Blood glucose (mg/dl) level in Experimental rats
###end p 29
###begin p 30
###xml 33 37 <span type="species:ncbi:10116">rats</span>
###xml 79 83 <span type="species:ncbi:10116">rats</span>
Values are mean +/- S.E.M of 4-6 rats in each group. Each group consist of 6-8 rats
###end p 30
###begin p 31
###xml 40 50 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#968;&#968;&#968; </sup>
*** P < 0.001 when compared to control, psipsipsi P < 0.001 when compared to diabetic group, phiphiphi p < 0.001 when compared with initial reading
###end p 31
###begin title 32
###xml 71 75 <span type="species:ncbi:10116">rats</span>
Acetylcholine esterase activity in the Corpus striatum of experimental rats
###end title 32
###begin p 33
###xml 53 57 53 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 218 222 218 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Acetylcholine esterase kinetics studies showed that Vmax was significantly decreased (p < 0.001) in the corpus striatum of diabetic group with no significant change in Km. Insulin treatment significantly reversed the Vmax (p < 0.001) to near control value when compared to diabetic group (Table 2).
###end p 33
###begin p 34
###xml 90 94 <span type="species:ncbi:10116">rats</span>
Acetylcholine esterase activity in the corpus striatum of Control, Diabetic and D+I group rats
###end p 34
###begin p 35
###xml 81 85 <span type="species:ncbi:10116">rats</span>
Values are mean +/- S.E.M of 4-6 separate experiments. Each group consist of 6-8 rats
###end p 35
###begin p 36
###xml 40 50 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#968;&#968;&#968; </sup>
*** P < 0.001 when compared to control, psipsipsi P < 0.001 when compared to diabetic group
###end p 36
###begin title 37
Total Muscarinic receptor analysis
###end title 37
###begin title 38
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 138 142 <span type="species:ncbi:10116">rats</span>
Scatchard analysis of [3H] QNB binding against atropine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated diabetic rats
###end title 38
###begin p 39
###xml 40 44 40 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 226 230 226 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 235 237 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 154 158 <span type="species:ncbi:10116">rats</span>
The Scatchard analysis showed that the Bmax and Kd of the [3H]QNB receptor binding decreased significantly (p < 0.001) in the corpus striatum of diabetic rats when compared to control group. In insulin treated diabetic group Bmax and Kd were significantly (p < 0.001) reversed back to near control value when compared to diabetic group. (Fig 1 & Table 3)
###end p 39
###begin p 40
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 167 0 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative graph showing Scatchard analysis of [<sup>3</sup>H]QNB binding against atropine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats</bold>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 163 167 <span type="species:ncbi:10116">rats</span>
###xml 242 246 <span type="species:ncbi:10116">rats</span>
Representative graph showing Scatchard analysis of [3H]QNB binding against atropine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (open circle), Insulin treated diabetic rats (black triangle). Total muscarinic receptor binding parameter assays were done using different concentrations i.e., 0.1-2.5 nM of [3H]QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 mul containing appropriate protein concentrations (200-250 mug). Non-specific binding was determined using 100 muM atropine. Tubes were incubated at 22degreesC for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by three successive washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
###end p 40
###begin p 41
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 136 140 <span type="species:ncbi:10116">rats</span>
Scatchard analysis of [3H] QNB binding against atropine in the corpus striatum of Control, Diabetic, and Diabetic+Insulin treated group rats
###end p 41
###begin p 42
###xml 81 85 <span type="species:ncbi:10116">rats</span>
Values are mean +/- S.E.M of 4-6 separate experiments. Each group consist of 6-8 rats
###end p 42
###begin p 43
###xml 40 50 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#968;&#968;&#968; </sup>
*** P < 0.001 when compared to control, psipsipsi P < 0.001 when compared to diabetic group
###end p 43
###begin title 44
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Displacement analysis of [3H]QNB using Atropine
###end title 44
###begin p 45
###xml 148 150 148 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
In the displacement analysis, the competitive curve fitted to a one-sited model in all groups with Hill slope values were near to unity. The log (EC50) did not alter in all the experimental groups. The Ki decreased in diabetic condition (Fig 2 & Table 4).
###end p 45
###begin p 46
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 167 0 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative graph showing displacement analysis of [<sup>3</sup>H]QNB binding against atropine in the hypothalamus of Control, Diabetic and Diabetic+Insulin treated group rats</bold>
###xml 350 351 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9</sup>
###xml 420 423 420 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 523 525 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 580 583 580 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 163 167 <span type="species:ncbi:10116">rats</span>
###xml 261 265 <span type="species:ncbi:10116">rats</span>
Representative graph showing displacement analysis of [3H]QNB binding against atropine in the hypothalamus of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (upward pointing black triangle), Insulin treated diabetic rats (downward pointing black triangle). Competition studies were carried out with 1 nM [3H]QNB in each tube with atropine concentrations varying from 10-9, 10-4 M. Data were fitted with iterative nonlinear regression software (Prism, GraphPad, San Diego, CA). Ki The affinity of the receptor for the competing drug. EC50 is the concentration of the competitor that competes for half the specific binding.
###end p 46
###begin p 47
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 127 131 <span type="species:ncbi:10116">rats</span>
Binding parameters of [3H] QNB against atropine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats
###end p 47
###begin p 48
###xml 71 75 <span type="species:ncbi:10116">rats</span>
Values are mean of 4-6 separate experiments. Each group consist of 6-8 rats
###end p 48
###begin title 49
Muscarinic M1 receptor analysis
###end title 49
###begin title 50
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 141 145 <span type="species:ncbi:10116">rats</span>
Scatchard analysis of [3H]QNB binding against pirenzepine in the corpus striatum of Control, Diabetic, and Diabetic+Insulin treated diabetic rats
###end title 50
###begin p 51
###xml 40 44 40 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 194 196 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 302 306 302 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 409 411 409 411 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 296 300 <span type="species:ncbi:10116">rats</span>
The Scatchard analysis showed that the Bmax of muscarinic M1 receptors of corpus striatum was increased significantly (p < 0.001) in diabetic condition when compared to control group while the Kd was decreased significantly when compared to control group (p < 0.001). In insulin treated diabetic rats Bmax was significantly (p < 0.001) reversed back to near control value when compared to diabetic group but Kd was not reversed back to near control value when compared to diabetic group (Fig 3 & Table 5).
###end p 51
###begin p 52
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 170 0 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative graph showing Scatchard analysis of [<sup>3</sup>H]QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats</bold>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 166 170 <span type="species:ncbi:10116">rats</span>
###xml 245 249 <span type="species:ncbi:10116">rats</span>
Representative graph showing Scatchard analysis of [3H]QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (open circle), Insulin treated diabetic rats (black triangle). Muscarinic M1 receptor binding parameter assays were done using different concentrations i.e., 0.1-2.5 nM of [3H]QNB in the incubation buffer, pH 7.4 in a total incubation volume of 250 mul containing appropriate protein concentrations (200-250 mug). Non-specific binding was determined using 100 muM pirenzepine. Tubes were incubated at 22degreesC for 60 minutes and filtered rapidly through GF/C filters (Whatman). The filters were washed quickly by three successive washing with 5.0 ml of ice cold 50 mM Tris-HCl buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 1409 liquid scintillation counter. The non-specific binding determined showed 10% in all our experiments.
###end p 52
###begin p 53
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 138 142 <span type="species:ncbi:10116">rats</span>
Scatchard analysis of [3H] QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats
###end p 53
###begin p 54
###xml 81 85 <span type="species:ncbi:10116">rats</span>
Values are mean +/- S.E.M of 4-6 separate experiments. Each group consist of 6-8 rats
###end p 54
###begin p 55
###xml 40 50 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#968;&#968;&#968; </sup>
*** P < 0.001 when compared to control, psipsipsi P < 0.001 when compared to diabetic group
###end p 55
###begin title 56
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Displacement analysis of [3H]QNB using pirenzepine
###end title 56
###begin p 57
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
In the displacement analysis, the competitive curve fitted to a one-site model in all the experimental conditions. Hill slopes were near unity confirming the one-site model. There were no changes in the log (EC50) values. The Ki value was decreased in diabetic condition (Fig 4 & Table 6).
###end p 57
###begin p 58
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 173 0 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative graph showing displacement analysis of [<sup>3</sup>H]QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats</bold>
###xml 356 357 356 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 423 426 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9 </sup>
###xml 431 434 431 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 534 536 534 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 593 596 593 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 169 173 <span type="species:ncbi:10116">rats</span>
###xml 267 271 <span type="species:ncbi:10116">rats</span>
Representative graph showing displacement analysis of [3H]QNB binding against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats. Control (black circle), Diabetic (upward pointing black triangle), Insulin treated diabetic rats (downward pointing black triangle). Competition studies were carried out with 1 nM [3H]QNB in each tube with pirenzepine concentrations varying from 10-9 to 10-4 M. Data were fitted with iterative nonlinear regression software (Prism, GraphPad, San Diego, CA). Ki - The affinity of the receptor for the competing drug. EC50 is the concentration of the competitor that competes for half the specific binding.
###end p 58
###begin p 59
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 129 133 <span type="species:ncbi:10116">rats</span>
Binding parameters of [3H]QNB against pirenzepine in the corpus striatum of Control, Diabetic and Diabetic+Insulin treated group rats
###end p 59
###begin p 60
###xml 71 75 <span type="species:ncbi:10116">rats</span>
Values are mean of 4-6 separate experiments. Each group consist of 6-8 rats
###end p 60
###begin title 61
Real Time-PCR analysis
###end title 61
###begin p 62
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T7">7</xref>
###xml 205 209 <span type="species:ncbi:10116">rats</span>
Real Time-PCR analysis showed that the muscarinic M1 receptor gene expression was increased significantly (p < 0.01) in diabetic condition and it reversed to near control value in insulin treated diabetic rats (Fig 5 & Table 7).
###end p 62
###begin p 63
###xml 0 154 0 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative graph showing Real-Time amplification of muscarinic M1 mRNA from the corpus striatum of control, diabetic and insulin treated diabetic rats</bold>
###xml 492 499 477 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Target </sub>
###xml 587 594 557 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Control</sub>
###xml 647 660 617 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;CT</sup>
###xml 696 709 658 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;CT</sup>
###xml 150 154 <span type="species:ncbi:10116">rats</span>
###xml 200 204 <span type="species:ncbi:10116">rats</span>
Representative graph showing Real-Time amplification of muscarinic M1 mRNA from the corpus striatum of control, diabetic and insulin treated diabetic rats. Control, Diabetic, Insulin treated diabetic rats. The DeltaDeltaCT method of relative quantification was used to determine the fold change in expression. This was done by first normalizing the resulting threshold cycle (CT) values of the target mRNAs to the CT values of the internal control beta-actin in the same samples (DeltaCT = CTTarget - CT beta-actin). It was further normalize with the control (DeltaDeltaCT = DeltaCT - CTControl). The fold change in expression was then obtained (2-DeltaDeltaCT). The graph was plotted using log 2-DeltaDeltaCT. Values are mean +/- S.D of 4-6 separate experiments. Relative Quantification values and standard deviations are shown in the table. The relative ratios of mRNA levels were calculated using the DeltaDeltaCT method normalized with beta-actin CT value as the internal control and Control CT value as the calibrator.
###end p 63
###begin p 64
###xml 137 141 <span type="species:ncbi:10116">rats</span>
Real Time amplification of Muscarinic M1 receptor mRNA from the Corpus striatum of Control, Diabetic, and Diabetic+Insulin treated group rats
###end p 64
###begin p 65
###xml 79 83 <span type="species:ncbi:10116">rats</span>
Values are mean +/- S.D of 4-6 separate experiments. Each group consist of 6-8 rats Relative Quantification values and standard deviations are shown in the table. The relative ratios of mRNA levels were calculated using the DeltaDeltaCT method normalized with beta-actin CT value as the internal control and Control CT value as the calibrator.
###end p 65
###begin p 66
** p < 0.01 when compared with control
###end p 66
###begin p 67
###xml 0 6 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#968;&#968;</sup>
psipsip < 0.01 when compared with diabetic group
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 615 617 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 822 824 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 825 827 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1037 1039 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1040 1042 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1209 1211 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1212 1213 1203 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1403 1405 1394 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1406 1408 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1412 1414 1403 1405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1539 1541 1530 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1542 1544 1533 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1545 1547 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1579 1581 1570 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1722 1724 1713 1715 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1817 1819 1808 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1820 1822 1811 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1823 1825 1814 1816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1969 1971 1960 1962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 2039 2041 2030 2032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 2141 2143 2132 2134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 2405 2407 2396 2398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2408 2410 2399 2401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2477 2479 2468 2470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 2510 2512 2501 2503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 2668 2669 2659 2660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2672 2673 2663 2664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2676 2677 2667 2668 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 2684 2685 2675 2676 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 2734 2736 2722 2724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 2851 2853 2839 2841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 3201 3203 3189 3191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 3204 3206 3192 3194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 3248 3252 3236 3240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 3396 3398 3384 3386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 5112 5114 5100 5102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 5115 5117 5103 5105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 313 317 <span type="species:ncbi:10116">rats</span>
###xml 2347 2351 <span type="species:ncbi:10116">rats</span>
###xml 3306 3310 <span type="species:ncbi:10116">rats</span>
###xml 3528 3532 <span type="species:ncbi:10116">rats</span>
###xml 4096 4100 <span type="species:ncbi:10116">rats</span>
###xml 4363 4367 <span type="species:ncbi:10116">rats</span>
The brain neurotransmitters receptor activity and hormonal pathways control many physiological functions in the body. The present study analyzed the changes of acetylcholine esterase enzyme activity, total muscarinic and muscarinic M1 receptors in the corpus striatum of STZ diabetic and insulin-treated diabetic rats. CNS mAChRs regulate a large number of important central functions including cognitive, behavioural, sensory, motor and autonomic processes [25-27]. A key feature of type 2 diabetes is that pancreatic beta-cells fail to release sufficient amounts of insulin despite elevated blood glucose levels [28]. Glucose-stimulated insulin secretion (GSIS) is regulated by numerous hormones and neurotransmitters most of which act on specific G-protein-coupled receptors (GPCRs) expressed by pancreatic beta-cells [29,30]. Many studies have shown that ACh, following its release from intra-pancreatic parasympathetic nerve endings, can stimulate beta-cell mAChRs, leading to enhanced GSIS in a strictly glucose-dependent fashion [29,30]. mAChRs are members of the superfamily of GPCRs. Molecular-cloning studies have revealed the existence of five molecularly distinct mammalian mAChR subtypes, M1-M5 [31,9]. Earlier studies from our laboratory have established the central neurotransmitter receptor subtypes functional regulation during diabetes, pancreatic regeneration and cell proliferation [32-37]. M1 mAChRs are abundantly expressed in all major regions of the forebrain, including striatum, hippocampus, and cerebral cortex [38-40,15]. It is therefore likely that M1 mAChRs play a role in the many central actions of ACh that involve the activity of forebrain mAChRs. Pharmacological evidence suggests that M1 receptors are involved in mediating higher cognitive processes, such as learning and memory [41,42,28]. The striatum, a neuronal nucleus intimately involved in motor behaviour, is one of the brain regions with the highest acetylcholine content [43]. The mRNA for M1 is present in more than 80% of striatal neurons [44] including cholinergic neurons, substance P neurons, enkephalin neurons, and somatostatin neurons [45]. Recent studies from our laboratory have showed the significance of muscarinic and muscarinic M1 receptors in the cerebral cortex, hypothalamus, brainstem, and pancreatic islets of STZ induced diabetic rats and its functional regulation in insulin secretion. [13,14]. ACh, through vagal muscarinic and non-vagal muscarnic pathways [46] increases insulin secretion [47]. They function through muscarinic receptors present on pancreatic islet cells. Receptor localization studies suggest that multiple muscarinic receptors (M1, M3, M4, and M5) are expressed in pancreatic islets/beta-cells [48]. From our previous studies it was observed that muscarinic M1 receptors were down-regulated during STZ diabetes [13]. The enzyme AChE indirectly plays an important role in transmission of nerve impulse. It hydrolyses the ACh released at the cholinergic synapse and thus terminates the action of this neurotransmitter. In addition to their role in cholinergic transmission, cholinesterases may also play a role during morphogenesis and neurodegenerative diseases [49,50]. We observed a significant decrease in Vmax of acetylcholine esterase in the striatum of diabetic rats which was reversed to near control level by insulin treatment. Akmayev et al (1978) [51] showed that there is a difference in distribution of enzyme in the neurons of the central vagal nuclei in normal and adult male rats. It is suggested that the changes in the plasma glucose or insulin may be that stimulus that influence the activity of cholinergic neurons. Insulin treatment reversed the altered maximum velocity toward the control level. Corpus striatum is best known for its role in the planning and modulation movement pathways but also involved in a variety of cognitive process involving executive function. In corpus striatum total muscarinic receptor numbers and affinity were decreased during diabetes, whereas muscarinic M1 receptors number was increased in STZ diabetic rats with decrease in affinity. The changes in the receptor number and affinity observed are due to the alterations of receptor protein and synthesis. Real-time PCR analysis showed an up-regulation of the muscarinic M1 receptor mRNA level in the striatum of diabetic rats, whereas it reversed to near control when treated with insulin. This is in accordance with our receptor binding studies. ACh has complex and clinically important actions in the striaturn that are mediated predominantly by muscarinic receptors. Based on physiological and pharmacological studies, several specific actions of ACh in the striatum have been suggested. ACh regulates its own release from cholinergic interneurons through presynaptic autoreceptors. Noncholinergic striatal neurons are directly affected by ACh through postsynaptic receptors and presynaptic heteroceptors and the release of excitatory amino acids and dopamine by extrinsic striatal afferents may be under presynaptic control of ACh through presynaptic heteroceptors [52-54]. In diabetic corpus striatum total muscarinic receptors activities were decreased. The insulin treatment reversed these altered parameters to near control level. Muscarinic receptor subtypes other than M1 may also be affected by the diabetic condition. Further studies have to be carried out to elucidate the role of other subtypes. The present study suggests that drugs that can selectively activate muscarinic receptors may be of significant therapeutic benefit in the diabetes management. Thus our results revealed the significance of central muscarinic receptor changes during diabetes and the regulatory role of insulin on muscarinic receptors.
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The authors declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
GG and CSP designed research; GG performed experiments; PKT and JM helped GG in experiments; GG and CSP analyzed the data; GG and CSP wrote the paper. All authors read and approved the final manuscript.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
This work was supported by a research grant from KSCSTE, Govt. of Kerala, DST, and ICMR, Govt. of India to Dr. C.S.Paulose. Gireesh.G thanks KSCSTE for JRF
###end p 75
###begin article-title 76
Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome
###end article-title 76
###begin article-title 77
###xml 89 93 <span type="species:ncbi:10116">rats</span>
Reduced anorexic and locomotor - stimulant action of d-amphetamine in alloxan - diabetic rats
###end article-title 77
###begin article-title 78
###xml 51 54 <span type="species:ncbi:10116">rat</span>
Further analysis of the resistance of the diabetic rat to d-amphetamine
###end article-title 78
###begin article-title 79
###xml 75 79 <span type="species:ncbi:10116">rats</span>
Morphological changes in the hypothalamic-hypophyseal-gonodal axis of male rats after twelve months of streptozotocin induced diabetes
###end article-title 79
###begin article-title 80
Diabetic encephalopathy. Diffuse and focal lesions of the brain in long-term diabetes
###end article-title 80
###begin article-title 81
###xml 64 68 <span type="species:ncbi:10116">rats</span>
###xml 73 76 <span type="species:ncbi:9606">man</span>
Dopamine, norepinephrine and serotonin in the brain of diabetic rats and man
###end article-title 81
###begin article-title 82
###xml 61 65 <span type="species:ncbi:10116">rats</span>
Dibetes induced alterations in brain monoamine metabolism in rats
###end article-title 82
###begin article-title 83
###xml 45 49 <span type="species:ncbi:10116">rats</span>
Dopaminergic activity is reduced in diabetic rats
###end article-title 83
###begin article-title 84
Classification of muscarinic acetylcholine receptors
###end article-title 84
###begin article-title 85
###xml 123 127 <span type="species:ncbi:10116">rats</span>
The concentrations of dopamine 5 Hydroxytryptamine and some of their acid metabolites in the brain of genetically diabetic rats
###end article-title 85
###begin article-title 86
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Effects of short and long-lasting diabetes mellitus on mouse brain monoamines
###end article-title 86
###begin article-title 87
###xml 73 77 <span type="species:ncbi:10116">rats</span>
Brain catecholamine concentrations in hyperosmolar diabetic and diabetic rats
###end article-title 87
###begin article-title 88
###xml 138 142 <span type="species:ncbi:10116">rats</span>
Decreased muscarinic M1 receptor gene expression in the hypothalamus, brainstem, and pancreatic islets of streptozotocin-induced diabetic rats
###end article-title 88
###begin article-title 89
###xml 116 132 116 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aegle marmelose </italic>
###xml 107 111 <span type="species:ncbi:10116">rats</span>
Decreased muscarinic M1 receptor gene expression in the cerebral cortex of streptozotocin-induced diabetic rats and Aegle marmelose leaf extract's therapeutic function J
###end article-title 89
###begin article-title 90
Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies
###end article-title 90
###begin article-title 91
###xml 122 125 <span type="species:ncbi:10116">rat</span>
Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distributions of m4 and m5 receptors in rat brain
###end article-title 91
###begin article-title 92
Diabetogenic action of Streptozotocin: Relationship of dose to metabolic response
###end article-title 92
###begin article-title 93
Kidney functions in experimental diabetic ketosis
###end article-title 93
###begin article-title 94
###xml 44 48 <span type="species:ncbi:10116">rats</span>
Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin
###end article-title 94
###begin article-title 95
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 42 45 <span type="species:ncbi:10116">rat</span>
Regional studies of catecholamines in the rat brain: the disposition of [3H] norepinephrine, [3H] dopa in various regions of brain
###end article-title 95
###begin article-title 96
A new and rapid colorimetric determination of acetylcholinesterase activity
###end article-title 96
###begin article-title 97
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 23 26 <span type="species:ncbi:10116">rat</span>
Binding of [3H] QNB in rat brain. Proc
###end article-title 97
###begin article-title 98
Protein measurement with Folin Phenol reagent
###end article-title 98
###begin article-title 99
The attraction of proteins for small molecules and ions
###end article-title 99
###begin article-title 100
Therapeutic opportunities for muscarinic receptors in the central nervous system
###end article-title 100
###begin article-title 101
Molecular biology of muscarinic acetylcholine receptors
###end article-title 101
###begin article-title 102
Muscarinic receptor subtype pharmacology and physiology
###end article-title 102
###begin article-title 103
The importance of betacell failure in the development and progression of type 2 diabetes
###end article-title 103
###begin article-title 104
Autonomic regulation of islet hormone secretion - implications for health and disease
###end article-title 104
###begin article-title 105
Mechanisms and physiological significance of the cholinergic control of pancreatic betacell function
###end article-title 105
###begin article-title 106
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications
###end article-title 106
###begin article-title 107
###xml 49 52 <span type="species:ncbi:10116">rat</span>
Induction of DNA synthesis in primary culture of rat hepatocyte by serotonin: Possible involvement of serotonin S2 receptor
###end article-title 107
###begin article-title 108
Hepatic GABA A receptor functional regulation during liver cell proliferation
###end article-title 108
###begin article-title 109
###xml 148 151 <span type="species:ncbi:10116">rat</span>
Alterations in the muscarinic M1 and M3 receptor gene expression in the brain stem during pancreatic regeneration and insulin secretion in weanling rat
###end article-title 109
###begin article-title 110
###xml 141 145 <span type="species:ncbi:10116">rats</span>
Decreased 5-HT1A receptor gene expression and 5HT1A receptor protein in the cerebral cortex and brain stem during pancreatic regeneration in rats
###end article-title 110
###begin article-title 111
###xml 86 90 <span type="species:ncbi:10116">rats</span>
Decreased GABAA receptor function in the brain stem during pancreatic regeneration in rats
###end article-title 111
###begin article-title 112
###xml 91 95 <span type="species:ncbi:10116">rats</span>
Age related alterations in noradrenergic function in brain stem of streptozotocin-diabetic rats
###end article-title 112
###begin article-title 113
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
Immunological localization of M1-M5 muscarinic acetylcholine receptors in peripheral tissues and brain
###end article-title 113
###begin article-title 114
Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors
###end article-title 114
###begin article-title 115
Development of selective antisera for muscarinic cholinergic receptor subtypes
###end article-title 115
###begin article-title 116
###xml 32 37 <span type="species:ncbi:9606">human</span>
Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease
###end article-title 116
###begin article-title 117
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update
###end article-title 117
###begin article-title 118
###xml 120 123 <span type="species:ncbi:10116">rat</span>
A mapping of the distribution of acetylcholine, choline acetyltransferase and acetylcholinesterase in discrete areas of rat brain
###end article-title 118
###begin article-title 119
###xml 70 73 <span type="species:ncbi:10116">rat</span>
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia
###end article-title 119
###begin article-title 120
###xml 37 40 <span type="species:ncbi:10116">rat</span>
Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes
###end article-title 120
###begin article-title 121
###xml 103 107 <span type="species:ncbi:9615">dogs</span>
Neural modulation of glucose-dependent insulinotropic peptide (GIP) and insulin secretion in conscious dogs
###end article-title 121
###begin article-title 122
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
Insulin secretion from ob/ob mouse pancreatic islets: effects of neurotransmitters
###end article-title 122
###begin article-title 123
###xml 113 116 <span type="species:ncbi:10116">rat</span>
Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets
###end article-title 123
###begin article-title 124
A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme
###end article-title 124
###begin article-title 125
###xml 140 145 <span type="species:ncbi:9031">chick</span>
Quantitative development and molecular forms of acetylcholinesterase and butyrylcholinesterase during morphogenesi s and synaptogenesi s of chick brain and retina
###end article-title 125
###begin article-title 126
CNS-endocrine pancreas system. IV. Evidence for the existence of a direct hypothalamic-vagal descending pathway
###end article-title 126
###begin article-title 127
###xml 74 77 <span type="species:ncbi:10116">rat</span>
Bindingof selective antagonists to four muscarinic receptors (M1 - M4) in rat forebrain
###end article-title 127
###begin article-title 128
###xml 93 96 <span type="species:ncbi:10116">rat</span>
Regional distribution of M 1, M2 and non- Ml, non-M2 subtypes of muscarinic binding sites in rat brain
###end article-title 128
###begin article-title 129
Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain
###end article-title 129

